---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-055883"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2025-04-18T23:59:59+00:00"
generated_at: "2026-05-23T10:53:56.827336+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics appoints Kyle Guse to board; Greg Petersen resigns

## Summary
- Kyle Guse appointed to board effective April 18, 2025, filling vacancy from Greg Petersen's resignation.
- Guse named to Audit Committee (Chair) and Compensation Committee; board deemed independent under Nasdaq rules.
- Greg Petersen resigned same day; no disagreement with company operations, policies, or practices.
- Guse is Chief Legal Officer at DDC Enterprise; previously CFO/GC at Atossa Therapeutics.
- Guse brings 30 years of experience in finance, corporate governance, and M&A; will stand for reelection.

## SEC filing metadata
- accession: 0000950170-25-055883
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2025-04-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000095017025055883/0000950170-25-055883-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000095017025055883/pstv-20250417.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-055883
- JSON: https://secwatch.observer/filing/0000950170-25-055883.json
- Plain text: https://secwatch.observer/filing/0000950170-25-055883.txt

## Source-grounded claims
- claim_id: 319469abdc
  claim: Greg Petersen resigned as Director at PLUS THERAPEUTICS, INC..
  evidence_excerpt: On April 18, 2025, Mr. Greg Petersen resigned as a member of the Board. Mr. Petersen informed the Company that his resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017025055883/0000950170-25-055883-index.htm
- claim_id: 7fb8b98100
  claim: Kyle Guse was appointed as Director at PLUS THERAPEUTICS, INC..
  evidence_excerpt: On April 18, 2025, the Board of Directors (the “Board”) of Plus Therapeutics, Inc (the “Company”) unanimously appointed Mr. Kyle Guse to serve as a director of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017025055883/0000950170-25-055883-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.